Raising awareness of the risk of post-traumatic hypopituitarism following a head injury must be increased among healthcare professionals, say campaigners. Thousands of people, in the UK alone ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

While it sends some signals about the priorities of new FDA Commissioner Dr Martin Makary, the actual impact of the directive ...

GSK's Blenrep (belantamab mafodotin) has officially been approved by the UK's Medicines and Healthcare products Regulatory ...

An international agreement on pandemic preparedness is finally complete after three years of negotiation. The World Health ...

Merida Biosciences has emerged from Third Rock Ventures with $121 million in first-round financing for a pipeline of drugs ...

This new approach to lab space is emblematic of a broader trend in real estate: the conversion of under-utilised office space ...

Pursue advocacy efforts We’ve seen critical legal decisions over the last five years either accelerate or stymie the United States biosimilar market. In the 2017 Amgen v. Sandoz case, the ...

1 Day. 20 Pharma Senior Speakers From GSK, Pfizer, AstraZeneca & More Explore Impactful, Value-Adding & Engaging Pharma Comms Strategies! Book 4 For The Price Of 3! Limited Discounted Places ...

With more than 80 per cent of European doctors saying they want to stay abreast of new developments about pharmaceutical products, it is important to understand how they wish to receive this ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

Novartis has said it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, after announcing a major delay to the biotech's lead programme pelabresib.